Solana Company (HSDT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HSDT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Solana Company (HSDT) Q2 2026 Earnings Call Transcript
Solana Company (HSDT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $79.73 per share a year ago.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $15 | $2.33 | -$12.67 | -84.47% |
Hui Fai Tam Caitong International Asset Management Co. Ltd. | 192 | $317.08 | $451.2 | $134.12 | 42.3% |
Ian Jameson American Capital Advisory, LLC | 235 | $3,500 | $544.02 | -$2,955.98 | -84.46% |
Highline Wealth Partners LLC Highline Wealth Partners LLC | 500 | $1,445 | $1,175 | -$270 | -18.69% |
| GPW Grant Private Wealth Management Inc. Grant Private Wealth Management Inc. | 25,005 | $61,592.13 | $58,486.69 | -$3,105.44 | -5.04% |
| Financial Services Industry | Financials Sector | Dane Carl Andreeff CEO | NASDAQ (CM) Exchange | 42328V876 CUSIP |
| US Country | 21 Employees | 4 Jan 2021 Last Dividend | 1 Jul 2025 Last Split | 27 Jun 2014 IPO Date |
Helius Medical Technologies, Inc. stands out as a pioneering company in the realm of neurotechnology with its focus straddling the development, licensing, and procurement of innovative non-implantable technologies aimed at ameliorating symptoms attributable to neurological disorders or injuries. Founded in 2014, this firm has set its base in Newtown, Pennsylvania, marking its commitment towards delivering groundbreaking solutions to enhance neurological health and function.
This avant-garde, non-surgical medical device represents Helius Medical Technologies' flagship offering. It’s specifically engineered for short-term treatment of gait deficits stemming from multiple sclerosis and balance deficits due to mild-to-moderate traumatic brain injury. A key aspect of its application involves concurrent utilization with supervised therapeutic exercises, highlighting its role as a supplementary treatment modality designed to foster improved neurological function.